Latest
Science & Space

FDA Approves First-in-Class Daily Pill Sunharbo, Slashing Repeat Stroke Risk by 26%

The FDA approved Bayer's once-daily oral Factor XIa inhibitor Sunharbo (asundexian) for secondary stroke prevention, backed by the 12,000-patient OCEANIC-STROKE trial showing a 26% reduction in recurrent ischemic strokes without increased major bleeding.

Read the story
Science & Space · Read the story
Newstro Science & Space section banner.
Newstro
Share this story

Landmark regulatory green light delivers first Factor XIa inhibitor to prevent recurrent vascular brain attacks

Silver Spring, Md. — November 14, 2026 · 7:45 a.m. CST.

In a historic therapeutic breakthrough for neurological medicine, the U.S. Food and Drug Administration (FDA) has formally approved Sunharbo (asundexian), a groundbreaking once-daily oral tablet that fundamentally alters how clinicians protect survivors of mild-to-moderate ischemic strokes and high-risk mini-strokes from debilitating recurrent episodes.

Developed by pharmaceutical leader Bayer, Sunharbo becomes the first-ever approved Factor XIa (FXIa) inhibitor in medical history. Taken as a 50-milligram tablet once daily in combination with standard antiplatelet medications such as aspirin or clopidogrel, the therapy was shown in massive international trials to slash the relative risk of a second ischemic stroke by 26 percent compared to standard therapy alone.

For decades, vascular neurologists have faced a perilous balancing act when treating stroke patients: aggressive blood-thinning drugs reduce the odds of fresh arterial blood clots, but they carry a severe, often lethal risk of triggering catastrophic hemorrhages and internal bleeding elsewhere in the body. Because Factor XIa selectively participates in pathologic thrombus expansion while largely sparing the body’s essential physiological clotting response to physical injury (hemostasis), Sunharbo achieved its protective benefit without causing a statistically significant increase in overall major bleeding.

OCEANIC-STROKE trial of 12,300 patients demonstrates robust secondary protection

The regulatory approval rests upon conclusive evidence from the landmark Phase 3 OCEANIC-STROKE clinical trial, one of the most comprehensive cardiovascular studies ever conducted. The trial evaluated more than 12,300 adult patients across hundreds of medical centers in over 30 countries who had recently suffered either a mild-to-moderate non-cardioembolic ischemic stroke (defined as an NIH Stroke Scale score of 15 or lower) or a high-risk transient ischemic attack (TIA).

Patients initiated treatment within 72 hours of symptom onset, receiving either 50 mg of daily asundexian or a matching placebo alongside established background antiplatelet regimens. Over a median monitoring span of 14.2 months, patients receiving Sunharbo demonstrated a clear, statistically robust 26 percent reduction in subsequent ischemic strokes.

“Recurrent ischemic strokes are frequently far more devastating, disabling, and fatal than the initial incident,” noted leading clinical investigators. “Demonstrating a quarter-fold drop in recurrence within the critical first year following an index event represents the most meaningful advance in secondary stroke management in nearly two decades.”

Prescribing guidelines and age-related safety precautions outlined by FDA

The FDA’s prescribing label emphasizes that Sunharbo is specifically authorized for patients recovering from non-cardioembolic strokes—clots originating from arterial narrowing or local vascular disease rather than emboli originating within the heart. It is expressly not indicated for stroke prevention in individuals diagnosed with atrial fibrillation.

While overall rates of major and fatal bleeding in the OCEANIC-STROKE cohort were statistically indistinguishable between Sunharbo and placebo, federal regulators incorporated specific guidance for vulnerable demographics. Clinical data highlighted a moderate uptick in bleeding vulnerability among patients aged 75 and older, as well as during the initial 90-day window following treatment initiation.

Gastrointestinal bleeding events were also slightly elevated in the treatment arm, while mild, self-limiting diarrhea was identified as the single most commonly reported adverse side effect. Neurologists caution that stroke prevention therapy must strictly be initiated and calibrated by licensed physicians, who will weigh patient kidney function, age, and concurrent medications.

Regulatory center: FDA White Oak Campus in Silver Spring, Maryland

The interactive map below marks the headquarters of the U.S. Food and Drug Administration at the White Oak Federal Research Center in Silver Spring, Maryland, where the review and approval of Sunharbo took place.

Map data: © OpenStreetMap contributors, ODbL.

Chronology: The scientific development and approval of Sunharbo

Major milestones in the clinical progression of Factor XIa inhibition for secondary stroke prevention:

  1. — Early clinical pharmacology trials demonstrate that selective inhibition of Factor XIa suppresses thrombin generation without extending baseline bleeding time.
  2. — Bayer launches the global Phase 3 OCEANIC-STROKE clinical program, enrolling over 12,300 high-risk stroke and TIA survivors worldwide.
  3. — Data monitoring committees report that OCEANIC-STROKE met its primary efficacy endpoint, confirming a 26% relative risk reduction in recurrent stroke.
  4. — The FDA accepts Bayer's New Drug Application (NDA) for asundexian under priority review status.
  5. — The FDA grants formal commercial approval for Sunharbo (asundexian) 50 mg daily tablets for secondary ischemic stroke prevention.